Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Tries Again With US Pegfilgrastim

Executive Summary

Sandoz has resubmitted its application for biosimilar pegfilgrastim to the FDA, having been knocked back with a complete response letter in 2016.

You may also be interested in...



Sandoz Expects Imminent US Pegfilgrastim Action

Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.

Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.

Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales

Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB140222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel